We are leveraging our
knowledge of new autophagy
biology to create new therapeutics
Samsara is leveraging its knowledge of new autophagy biology to rapidly advance multiple drug candidates to the clinic – promising new therapies designed to treat serious rare genetic diseases and neurodegenerative disorders with a strong genetic component. These diseases all have limited or no known treatment options.
We focus on identifying novel targets and mechanisms which have a strong genetic linkage to dysfunctional autophagy, and pair this new biology with the appropriate genetically driven disease where autophagy plays a driving role, and where we have generated strong in-house evidence of disease modification.
We caught up with Senior Scientists Gabriela Vilema Enríquez and Matthew Williamson on their work within the neuroscience team at Samsara.
CMT Research Foundation and Samsara Therapeutics Partner on a Novel Therapeutic Approach for CMT1A with the Potential to Reach Clinical Trials
Hear from Nicole Mak, a Biology student at Bath University, on her year in industry with Samsara.
Michael Schlossmacher, Susan Perlman, Ed Tate and Christian Behl to help advance development of neurodegeneration and rare genetic disease therapeutics